Treatment of T-helper cell type 2-mediated immune disease by ret

Details Treatment of T-helper cell type 2-mediated immune disease by ret Treatment of T-helper cell type 2-mediated immune disease by ret

1998-11-10

2000-10-17

Travers, Russell

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

A61K 3138

Patent

active

061333093

ABSTRACT:
Retinoids with retinoid receptor antagonistic activity, pharmaceutically acceptable salts and pharmaceutically acceptable hydrolyzable esters thereof, have been found efficacious in treating T-helper cell type 2 (Th2)-mediated immune diseases, such as immunoglobulin E (IgE)-mediated allergic diseases.

REFERENCES:
patent: 5391766 (1995-02-01), Klaus et al.
patent: 5512683 (1996-04-01), Klaus et al.
Apfel et al. PNAS, vol. 89, pp. 7129-33, Aug. 1992.
Racke et al., The Journal of Immunology, 154:450-458 (1995).
Pfahl et al., Vitamins and Hormones, 49:327-382 (1994).
Brinckerhoff et al., Science, 221:756-758 (1983).
Massacesi et al., J. Clin. Invest., 88:1331-1337 (1991).
Lee et al., The Journal of Biological Chemistry, 271(20):11897-11903 (1996).
Romagnani, Ann. Rev. Immunol., 12:227-257 (1994).
Robinson et al., Chem. Immunol., 63:187-203 (1996).
Abbas et al., Nature, 383:787-793 (1996).
Kips et al. Am. J. Respir. Crit. Care Med. 153:535-539 (1996).

Affiliated with

Also associated with

Rating

Treatment of T-helper cell type 2-mediated immune disease by ret does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of T-helper cell type 2-mediated immune disease by ret, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of T-helper cell type 2-mediated immune disease by ret will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-469578